title: [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].
abstract: Therapeutic intervention using oncolytic viruses is called virotherapy. This type of virus is defined by the ability to replicate in tumor cells only and to destroy these cells upon replication. In addition, this virus type is able to induce a tumor-directed immune response. Early clinical trials have confirmed the safety profile of oncolytic viruses. Currently, different groups are working on the development of oncolytic viruses with a focus on treatment of nonmuscle invasive bladder cancer (NMIBC). A preliminary active recruiting clinical phase II/III trial ongoing in patients with a NMIBC was recently implemented in the United States. Our research group developed an oncolytic adenovirus that will soon enter a clinical phase I trial in patients diagnosed with glioma. This virus is being further modified for the treatment of NMIBC. In this review article, recent developments in the design and use of virotherapy in bladder cancer are summarized.
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland. per.s.holm@lrz.tum.de.
authors.forename: P S
authors.initials: PS
authors.lastname: Holm
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Retz
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: J E
authors.initials: JE
authors.lastname: Gschwend
authors.affiliation: Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
authors.forename: R
authors.initials: R
authors.lastname: Nawroth
mesh_terms: D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000628:therapy* / Q000821:virology*; D019317:Evidence-Based Medicine; D006801:Humans; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology*
keywords: Adenovirus; Bladder cancer; Immunotherapy; Oncolytic virotherapy; Urogenital system